Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Foreign Inspections User Fee Program Getting Push On The Hill

Executive Summary

The pharmaceutical industry is facing an increasingly aggressive push to create user fees for manufacturing inspections.

You may also be interested in...



FDA’s Autor Moves To Mylan: Company’s Gain May Also Be Company’s Loss

While Mylan wants Autor to help push quality improvement efforts around the world, her departure from FDA may affect implementation of similar plans at the agency.

U.S. FDA Highlights Hands-On Approach To China Inspections In Budget Plan

The inspection focus of U.S. FDA’s budget request is largely on adding more personnel, but the agency continues to think about how best to target and leverage its resources in its globalization plan.

FDA Highlights Hands-On Approach To China Inspections In Budget Plan

The inspection focus of the budget request is largely on adding more personnel, but the agency continues to think about how best to target and leverage its resources in its globalization plan.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS053551

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel